BlinkLab

BlinkLab is pleased to be included in the recent @StockheadAU article "ASX healthcare breaks losing streak in good news week" Blinklab (ASX:BB1) had two positive announcements this week, including selection for Morocco’s nationwide, government funded autism screening program and commencement of enrolment for its pivotal study. Under a multi ministry national framework endorsed by King Mohammed VI, BB1’s Dx1 smartphone based screening tool will be deployed across Morocco for early autism screening from 18 months of age. Read more: stockhead.com.au/health/scott-p… $BB1.ax #awareness #autismspeaks

$BB1 - @BlinkLab (ASX:BB1) is pleased to talk to @ausbiztv about teaming up with Morocco for an autism screening program. Brian Leedman highlights a government-backed programme in Morocco, where Blinklab is selected as technology partner for a nationwide autism screening rollout. He notes that Morocco funds programme-related costs while Blinklab supplies the technology, generating what he views as invaluable real-world usability data ahead of formal regulatory approvals. Leedman points to an ongoing FDA study in North America, involving 10 leading hospitals including the Kennedy Krieger and Vanderbilt autism research centres, with completion targeted within months and US regulatory approval hoped for in 2025, followed by Europe, Australia and potentially China. 📺 Watch the interview - lnkd.in/gD_Sg-qn $BB1.ax #awareness hashtag#autismspeaks

Perth startup BlinkLab Limited (ASX:BB1) has secured the contract for a nationwide autism screening program in Morocco. The startup was founded by Princeton University neuroscientists and has developed an autism diagnostic platform that runs through smartphones. Its leading product, BlinkLab Dx1, is an autism diagnostic aid for clinicians that combines AI and machine learning to capture reflex-based measures to identify autism more accurately and earlier, allowing for intervention at critical periods of brain development. Read more: buff.ly/6qhDlRW $BB1.ax #awareness #autismspeaks

BlinkLab kicks off pivotal FDA 510(k) validation for Dx1 autism diagnostic aid; first participant enrolled as an 8-month study targeting end-2026 submission. The program is specifically designed to generate the core clinical and usability evidence required for a planned FDA 510(k) submission for the company's BlinkLab Dx1 pediatric autism diagnostic aid. Read more: buff.ly/2SR7Bdg $BB1.ax #awareness #autismspeaks

BlinkLab (ASX:BB1) is pleased to announce the commencement of its validation program supporting 510(k) submission, with the first child participant now enrolled and having completed initial testing using BlinkLab Dx1. Read more: buff.ly/z3c3RTa $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce its involvement in a landmark national autism screening and capacity-building initiative launched by the Kingdom of Morocco. This initiative is the first and most comprehensive of its kind worldwide, positioning Morocco as a leading example for the international community. With the launch of its government-led national autism screening program, Morocco intends to set a global precedent in autism screening. Read more: buff.ly/GeXbXa9 $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) has announced the completion of its clinical site network for a pivotal FDA 510(k) study, a critical step towards potential clearance of its BlinkLab Dx 1 device. This, coupled with strong pilot data, signals significant progress in the company's regulatory pathway. The company has officially onboarded 10 clinical sites across the US for the study, with the University of Arkansas the final site to be included in this comprehensive network. Read more: smallcaps.com.au/article/blinkl… $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that the University of Arkansas, a globally recognised research university in Fayetteville, Arkansas, has been onboarded as the tenth and final clinical site for the Company’s upcoming pivotal U.S. regulatory trial for BlinkLab Dx 1. Read more: buff.ly/OtVsFBj $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that it has entered into a new partnership with the SHANK2 Foundation, a U.S.-based notfor-profit organisation with a focus on advocacy, awareness, the creation of research infrastructure, as well as data collection and assistance with phenotyping studies on SHANK2-related neurodevelopmental disorders. Read more: buff.ly/SyuTlTw $BB1.ax #awareness #autismspeaks

US Capital access, cross-border deals and biotech - @blink_lab (BB1:ASX) Non-exec Chairman Brian Leedman in Singapore for @Hall_Chadwick forum #BlinkLab #biotech #investment #health #hallchadwick

$BB1 – @blink_lab Chairman, Brian Leedman, recently presented at the JMM Perth Investor Lunch. 📺 Watch the recording from the live event - youtu.be/Z1NF45UQFwo 🔗 Watch the JMM Insight series here: youtu.be/Z5CQaQxWoS0 Read @StockheadAU article buff.ly/H7nFqU0

BlinkLab Limited (ASX:BB1) is pleased to present its Half Yearly report, together with the financial statements of the Company for the half-year ended 31 December 2025. Read more: buff.ly/kurvSak $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1), a leader in AI-powered digital diagnostics, is pleased to announce that Drexel University, a globally recognised research university and innovator in neurodevelopmental research, has joined as a clinical site for the Company’s pivotal U.S. regulatory trial for BlinkLab Dx. Read more: buff.ly/6sfZVqm $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to provide an overview of its activities for the quarter ended 31 December 2025. Read more: buff.ly/2JvQI7I $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) was recently featured in @cmail_biz, highlighting the potential impact of its smartphone-based autism screening technology. The article outlines how BlinkLab Dx 1 is designed to enable a 15-minute, at-home screening experience, using AI to analyse a child’s involuntary responses to visual and audio stimuli. Results from BlinkLab’s recently completed US pilot study demonstrated sensitivity and specificity broadly comparable with existing clinical assessment methods. With FDA clearance already granted to commence its pivotal 510(k) trial in the United States, BlinkLab is preparing for an important next phase as it advances toward potential regulatory submission. Early, accessible screening has the potential to reduce wait times, lower costs for families, and support earlier clinical decision-making. Read the full article here: buff.ly/Bf1m5Ln $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that the Company’s Managing Director, CEO and Co-Founder, Dr Henk-Jan Boele, has been invited to participate as a speaker in an upcoming in-person workshop hosted by the Simons Foundation Autism Research Initiative (SFARI). Read more: buff.ly/Qb4Jfy8 $BB1.ax #awareness #autismspeaks

BlinkLab is pleased to be included in Stocks Down Under's recent article "5 ASX Healthcare Companies with Game Changing Milestones in 2026!" Read more: stocksdownunder.com/asx-healthcare… $BB1.ax

BlinkLab (ASX:BB1) is pleased to provide a recording from the recent interview where Jane Morgan talks to Professor Samuel Wang about the company's latest activities. 📺 Watch video youtu.be/w_9T9FYs6MA $BB1 #awareness #autismspeaks

BlinkLab (ASX:BB1) is pleased to provide a recording from the recent ausbiz interview. Chairman, Brian Leedman outlines how the technology uses a forward-facing camera to deliver visual and audio stimuli to a child, with AI analysing the response. 📺 Watch video buff.ly/iuktJpY $BB1.ax #awareness #autismspeaks